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In the present issue, the paper from van Dijk and col-
leagues is published without changes after the usual
peer reviewing process and it truly reflects the opinions
of the authors as they were independently expressed.
This editorial choice is not due only to the indisputable
interest of the concepts expressed,1 but also to the deci-
sion to publish ideas originated in the Cardiological
Community that we hope will generate further contri-
butions, responses and letters. The paper is contribut-
ing to the important debate on the recommendations
and their levels of evidences reported by the European
Guidelines, developed under the umbrella of the
European Society of Cardiology (ESC).
There is no doubt that Guidelines preparation and
update constitutes one of the pillars of the ESC, and
groups of experts in the field from across Europe are
commissioned to write and review documents accord-
ing to a structured process that extends over a two-year
period. This process finally involves around 100 experts
and influences the care provided to millions of people
worldwide.2
In recent years guidelines from both sides of the
Atlantic3,4 have increasingly been criticized for the lim-
ited amount of evidence underlying many of their rec-
ommendations. Multiple systematic analyses have
shown that a limited number (<15%) of the recommen-
dations in European and American cardiovascular
guidelines are supported by evidence from multiple ran-
domized controlled trials (RCTs) and meta-analyses.
Although very relevant, the meaning of these find-
ings can remain largely unclear as they lacked a detailed
breakdown to where (e.g. therapeutic versus diagnostic
recommendations) the suggested lack of evidence is
most problematic, unexpected, or potentially solvable.
To know which paucities in the evidence base are
problematic and where to focus improvement efforts to
them, it is necessary to identify areas of recommenda-
tions not supported by high-quality evidence and iden-
tify the underlying reasons. To reveal where gaps exist in
the current cardiovascular evidence base, and allow
better interpretation of the evidence underlying recom-
mendations, van Dijk and colleagues performed a really
valuable work trying to identify which types of recom-
mendations (e.g. therapeutic or diagnostic) and which
recommended actions (e.g. pharmaceutical intervention
or non-invasive imaging) are supported by which level of
evidence (LoE) in the Guidelines of the ESC.
They observed that with a median of 128 recommen-
dations per guideline, most recommendations were of
class I (47.7%), followed by class II (44.7%) and only
7.6% class III. However, only 14.1% of the recommen-
dations are supported by multiple RCTs or meta-ana-
lysis (LoE A). Moreover the evidence levels supporting
recommendations vary widely per:
1. Type. Recommendations on diagnostic topics were
supported by lower levels than recommendations on
therapeutic topics.
2. Recommended action. Recommendations on open
surgical interventions were less supported by RTCs
than were pharmaceutical and minimal-invasive
interventions.
3. Sub-specialty. Recommendations on the sub-
specialty of General Cardiology showed substan-
tially lower levels of evidence than, for instance,
the sub-specialty of Coronary Artery Disease.
Ten years ago, Tricoci et al.3 already reported simi-
lar findings for the American College of Cardiology/
American Heart Association guidelines, confirmed
more recently by Fonaroff et al.4 They identified several
shortcomings in the organization of clinical research
and guideline development process as possible explan-
ations for this shortage in recommendations supported
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by high-quality evidence. These shortcomings included
fragmentation of the research enterprise (a lack in
common goals, vision and collaboration), missing
incentives to fill evidence gaps and potential conflicts
of interests.
On the other side, RCTs are usually confined to
patients of specific ages with single conditions. There
will never be enough time, effort or funding to imple-
ment RCTs to address all clinical scenarios that confront
physicians. Individual patients are unique and many
differ from those enrolled in the RCTs on which the
guidelines are based, but consistent deviation should be
explained. Elderly individuals with multiple comorbid
conditions, who constitute an increasing number of
patients seen in clinical practice, are excluded from
most RCTs.5 This results in the common need to
extrapolate guideline recommendations built on ideal
patients to the real patients seen in practice, which has
elevated cardiovascular registries to a higher level of
prominence. Despite the imperfections of registry data,
which are often derived from administrative information
embedded in electronic health records and have the
potential for confounding inherent in non-randomized
databases, registries have the potential to confirm results
of RCTs or to extend them to individuals with more
complex, comorbid conditions.
It is unlikely that there will ever be RCTs confirming
that a routine blood sample should be performed as
soon as possible in the suspicion of acute coronary syn-
drome (LoE C), or that a haemoglobin and white blood
cell blood test and electrocardiogram should be per-
formed in patients with symptoms of heart failure
(LoE C), or that a multidisciplinary team is beneficial
when making management decisions for patients with
complex coronary artery disease or valvular heart dis-
ease (LoE C), or that parachutes can reduce the risk of
injury (Figure 1). The primacy of these recommenda-
tions ensures that guidelines remain patient-centric and
do not evolve to a just-the-facts recitation of data dis-
tilled from RCTs of tests, treatments and devices.
It should be understood that guidelines are not rules
but are what the word implies – guides. Guidelines pro-
vide advice to practising physicians, clarify contempor-
ary areas of consensus, but also of disagreement,
improve standards and guide clinical decision-making
for routine clinical practice. In all the preambles of ESC
Guidelines it is pointed out that they have been devel-
oped to support healthcare professionals and cannot
substitute for individual care and expertise. Health pro-
fessionals are encouraged to take the Guidelines fully
into account when exercising their clinical judgement,
as well as in the determination and the implementation
of preventive, diagnostic or therapeutic medical strate-
gies. However, the Guidelines do not override in any
way whatsoever the individual responsibility of health
professionals to make appropriate and accurate deci-
sions in consideration of each patient’s health condition
and in consultation with that patient and the patient’s
caregiver where appropriate and/or necessary.
So the paper from van Dijk and colleagues is very
much appreciated and provides crucial points of discus-
sion to a very important topic.
A final point: the authors criticize the current
Preventive Guidelines6 on the included topics on popu-
lation-based intervention because the related recom-
mendations do not provide therapeutic procedures, in
their opinion. But these guidelines for the first time
provide tools for healthcare professionals to promote
population-based strategies in all settings, with the aim
to integrate these into national or regional prevention
frameworks and to translate these in locally delivered
healthcare services, in line with the recommendations of
the World Health Organization global status report on
non-communicable diseases.
All these aspects are indeed open for a discussion
that will certainly contribute to awareness in cardiolo-
gists on the basis of their best clinical practice.
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Evidence of the « C » level 
is not necessarily weak!
Level of Evidence = C
Figure 1. Example of Level of C recommendation. Parachutes
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